Vaxcyte, Inc.
PCVX
$31.16
-$0.29-0.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 226.16% | 226.16% | 226.16% |
| Gross Profit | -- | -- | -226.16% | -226.16% | -226.16% |
| SG&A Expenses | 56.62% | 53.05% | 48.52% | 47.74% | 48.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.36% | 21.69% | 68.76% | 90.17% | 93.52% |
| Operating Income | -24.36% | -21.69% | -68.76% | -90.17% | -93.52% |
| Income Before Tax | -16.67% | -15.33% | -69.49% | -87.78% | -78.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.67% | -15.33% | -69.49% | -87.78% | -78.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.67% | -15.33% | -69.49% | -87.78% | -78.32% |
| EBIT | -24.36% | -21.69% | -68.76% | -90.17% | -93.52% |
| EBITDA | -23.44% | -21.01% | -68.75% | -90.63% | -94.20% |
| EPS Basic | 5.69% | 6.81% | -37.84% | -39.23% | -23.41% |
| Normalized Basic EPS | 5.68% | 6.80% | -37.88% | -39.27% | -23.44% |
| EPS Diluted | 5.69% | 6.81% | -37.84% | -39.23% | -23.41% |
| Normalized Diluted EPS | 5.68% | 6.80% | -37.88% | -39.27% | -23.44% |
| Average Basic Shares Outstanding | 23.65% | 25.58% | 24.72% | 33.17% | 43.72% |
| Average Diluted Shares Outstanding | 23.65% | 25.58% | 24.72% | 33.17% | 43.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |